ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)

Corey R. Hopkins

doi:10.1021/cn200084v

ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)

Corey R. Hopkins

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.

Original language	English (US)
Pages (from-to)	554
Number of pages	1
Journal	ACS Chemical Neuroscience
Volume	2
Issue number	10
DOIs	https://doi.org/10.1021/cn200084v
State	Published - Oct 19 2011
Externally published	Yes

Keywords

Depression
SSRI
antidepressant
major depressive disorder

ASJC Scopus subject areas

Biochemistry
Physiology
Cognitive Neuroscience
Cell Biology

Access to Document

10.1021/cn200084v

Fingerprint Dive into the research topics of 'ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)'. Together they form a unique fingerprint.

Cite this

@article{0491bf389b584aaab3fb4377e0c8c879,

title = "ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)",

abstract = "On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.",

keywords = "Depression, SSRI, antidepressant, major depressive disorder",

author = "Hopkins, {Corey R.}",

year = "2011",

month = oct,

day = "19",

doi = "10.1021/cn200084v",

language = "English (US)",

volume = "2",

pages = "554",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "10",

}

TY - JOUR

T1 - ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)

AU - Hopkins, Corey R.

PY - 2011/10/19

Y1 - 2011/10/19

N2 - On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.

AB - On January 21, 2011, the U.S. Food and Drug Administration approved Viibryd, a new selective serotonin reuptake inhibitor (SSRI), to treat major depressive disorder in adults developed by Clinical Data, Inc.

KW - Depression

KW - SSRI

KW - antidepressant

KW - major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=80054956583&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054956583&partnerID=8YFLogxK

U2 - 10.1021/cn200084v

DO - 10.1021/cn200084v

M3 - Article

C2 - 22860155

AN - SCOPUS:80054956583

VL - 2

SP - 554

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 10

ER -

ACS chemical neuroscience molecule spotlight on Viibryd (vilazodone)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this